Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations
01:16pm, Tuesday, 22'nd Jun 2021
– First selective MET inhibitor approval in China in this setting –
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors
11:24am, Friday, 18'th Jun 2021
– Second New Drug Application (“NDA”) approved for Sulanda in China –
HUTCHMED Launches Hong Kong Initial Public Offering
07:30pm, Thursday, 17'th Jun 2021
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 18, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today announces the launch of i
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
04:20pm, Sunday, 13'th Jun 2021
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program
02:00am, Thursday, 20'th May 2021
– HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 9 a.m. EDT to discuss data disclosures, its PD-1/L1 combination study strategy an
Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and Investors
02:00am, Monday, 17'th May 2021
– HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. EDT to provide updates on recent progress and upcoming milestones – – HUTCHMED will hold a webcast on Wednesday, May 26 at 8 a.m. ED
Change of Company Name
03:00am, Tuesday, 04'th May 2021
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM: HCM), formerly known as Hutchison China MediTech Limited, announces that, furt
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
07:00am, Monday, 03'rd May 2021
First NDA submission by HUTCHMED in the U.S.; product launch preparations underway First NDA submission by HUTCHMED in the U.S.; product launch preparations underway
HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China
02:00am, Thursday, 29'th Apr 2021
— Single-arm study in ~180 patients, with ORR as primary endpoint —
HUTCHMED Announces US$100 Million Equity Investment by Baring Private Equity Asia
03:30am, Thursday, 08'th Apr 2021
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
Moving Average Crossover Alert: Hutchison China MediTech (HCM)
07:35am, Wednesday, 07'th Apr 2021
Hutchison China MediTech (HCM) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
— HMPL-306 is the sixth innovative oncology drug candidate discovered in house by HUTCHMED to enter into global development — — HMPL-306 is the sixth innovative oncology drug candidate discove
HUTCHMED Enters Agreement to Divest Non-Core OTC Joint Venture for US$169 Million
09:30am, Wednesday, 24'th Mar 2021
Allows focus on China and global clinical development and market launches of key Oncology/Immunology assets Allows focus on China and global clinical development and market launches of key Oncology/I
HUTCHMED Initiates a Phase Ib/II Trial of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors
03:00am, Wednesday, 24'th Mar 2021
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) has initiated a Phase Ib/II study of surufatinib i
Hutchison China MediTech Limited's (HCM) CEO Christian Hogg on Q4 2020 Results - Earnings Call Transcript
03:03pm, Thursday, 04'th Mar 2021
Hutchison China MediTech Limited's (HCM) CEO Christian Hogg on Q4 2020 Results - Earnings Call Transcript
